vs

Side-by-side financial comparison of Immunocore Holdings plc (IMCR) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

REPLIGEN CORP is the larger business by last-quarter revenue ($197.9M vs $104.5M, roughly 1.9× Immunocore Holdings plc). On growth, Immunocore Holdings plc posted the faster year-over-year revenue change (24.3% vs 13.6%). REPLIGEN CORP produced more free cash flow last quarter ($17.6M vs $-35.5M). Over the past eight quarters, Immunocore Holdings plc's revenue compounded faster (21.7% CAGR vs 14.4%).

Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

IMCR vs RGEN — Head-to-Head

Bigger by revenue
RGEN
RGEN
1.9× larger
RGEN
$197.9M
$104.5M
IMCR
Growing faster (revenue YoY)
IMCR
IMCR
+10.7% gap
IMCR
24.3%
13.6%
RGEN
More free cash flow
RGEN
RGEN
$53.1M more FCF
RGEN
$17.6M
$-35.5M
IMCR
Faster 2-yr revenue CAGR
IMCR
IMCR
Annualised
IMCR
21.7%
14.4%
RGEN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IMCR
IMCR
RGEN
RGEN
Revenue
$104.5M
$197.9M
Net Profit
$13.3M
Gross Margin
97.4%
52.5%
Operating Margin
-18.8%
9.0%
Net Margin
6.7%
Revenue YoY
24.3%
13.6%
Net Profit YoY
143.9%
EPS (diluted)
$-0.61
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMCR
IMCR
RGEN
RGEN
Q4 25
$104.5M
$197.9M
Q3 25
$103.7M
$188.8M
Q2 25
$98.0M
$182.4M
Q1 25
$93.9M
$169.2M
Q4 24
$84.1M
$174.1M
Q3 24
$80.2M
$154.9M
Q2 24
$75.4M
$154.1M
Q1 24
$70.5M
$151.3M
Net Profit
IMCR
IMCR
RGEN
RGEN
Q4 25
$13.3M
Q3 25
$-177.0K
$14.9M
Q2 25
$-10.3M
$14.9M
Q1 25
$5.0M
$5.8M
Q4 24
$-30.3M
Q3 24
$8.7M
$-654.0K
Q2 24
$-11.6M
$3.3M
Q1 24
$-24.4M
$2.1M
Gross Margin
IMCR
IMCR
RGEN
RGEN
Q4 25
97.4%
52.5%
Q3 25
99.5%
53.2%
Q2 25
98.9%
50.0%
Q1 25
99.1%
53.6%
Q4 24
99.6%
26.1%
Q3 24
99.4%
50.0%
Q2 24
97.7%
49.8%
Q1 24
99.7%
49.5%
Operating Margin
IMCR
IMCR
RGEN
RGEN
Q4 25
-18.8%
9.0%
Q3 25
-6.9%
8.9%
Q2 25
-15.2%
7.6%
Q1 25
-3.9%
3.9%
Q4 24
-23.1%
-17.7%
Q3 24
-10.6%
-5.1%
Q2 24
-21.2%
1.0%
Q1 24
-37.6%
1.3%
Net Margin
IMCR
IMCR
RGEN
RGEN
Q4 25
6.7%
Q3 25
-0.2%
7.9%
Q2 25
-10.5%
8.2%
Q1 25
5.4%
3.4%
Q4 24
-17.4%
Q3 24
10.9%
-0.4%
Q2 24
-15.4%
2.2%
Q1 24
-34.7%
1.4%
EPS (diluted)
IMCR
IMCR
RGEN
RGEN
Q4 25
$-0.61
$0.24
Q3 25
$0.00
$0.26
Q2 25
$-0.20
$0.26
Q1 25
$0.10
$0.10
Q4 24
$-0.47
$-0.55
Q3 24
$0.17
$-0.01
Q2 24
$-0.23
$0.06
Q1 24
$-0.49
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMCR
IMCR
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$864.2M
$767.6M
Total DebtLower is stronger
$542.2M
Stockholders' EquityBook value
$381.0M
$2.1B
Total Assets
$1.1B
$2.9B
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMCR
IMCR
RGEN
RGEN
Q4 25
$864.2M
$767.6M
Q3 25
$892.4M
$748.7M
Q2 25
$882.8M
$708.9M
Q1 25
$837.0M
$697.2M
Q4 24
$820.4M
$757.4M
Q3 24
$901.3M
$784.0M
Q2 24
$859.6M
$809.1M
Q1 24
$832.8M
$780.6M
Total Debt
IMCR
IMCR
RGEN
RGEN
Q4 25
$542.2M
Q3 25
$537.9M
Q2 25
Q1 25
Q4 24
$525.6M
Q3 24
$438.7M
Q2 24
$452.5M
Q1 24
$452.5M
Stockholders' Equity
IMCR
IMCR
RGEN
RGEN
Q4 25
$381.0M
$2.1B
Q3 25
$396.6M
$2.1B
Q2 25
$388.5M
$2.1B
Q1 25
$378.5M
$2.0B
Q4 24
$360.7M
$2.0B
Q3 24
$377.8M
$2.0B
Q2 24
$359.1M
$2.0B
Q1 24
$359.5M
$2.0B
Total Assets
IMCR
IMCR
RGEN
RGEN
Q4 25
$1.1B
$2.9B
Q3 25
$1.1B
$2.9B
Q2 25
$1.1B
$2.9B
Q1 25
$1.0B
$2.9B
Q4 24
$1.0B
$2.8B
Q3 24
$1.1B
$2.8B
Q2 24
$1.0B
$2.9B
Q1 24
$994.0M
$2.8B
Debt / Equity
IMCR
IMCR
RGEN
RGEN
Q4 25
0.26×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.27×
Q3 24
1.16×
Q2 24
1.26×
Q1 24
1.26×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMCR
IMCR
RGEN
RGEN
Operating Cash FlowLast quarter
$-32.7M
$25.7M
Free Cash FlowOCF − Capex
$-35.5M
$17.6M
FCF MarginFCF / Revenue
-34.0%
8.9%
Capex IntensityCapex / Revenue
2.8%
4.1%
Cash ConversionOCF / Net Profit
1.93×
TTM Free Cash FlowTrailing 4 quarters
$-15.1M
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMCR
IMCR
RGEN
RGEN
Q4 25
$-32.7M
$25.7M
Q3 25
$-4.5M
$48.1M
Q2 25
$26.0M
$28.6M
Q1 25
$435.0K
$15.0M
Q4 24
$-14.0M
$39.2M
Q3 24
$21.1M
$49.3M
Q2 24
$23.5M
$42.2M
Q1 24
$-4.6M
$44.7M
Free Cash Flow
IMCR
IMCR
RGEN
RGEN
Q4 25
$-35.5M
$17.6M
Q3 25
$-5.2M
$43.4M
Q2 25
$25.6M
$21.5M
Q1 25
$137.0K
$11.4M
Q4 24
$-17.5M
$33.6M
Q3 24
$20.3M
$42.3M
Q2 24
$23.1M
$37.4M
Q1 24
$-5.0M
$36.4M
FCF Margin
IMCR
IMCR
RGEN
RGEN
Q4 25
-34.0%
8.9%
Q3 25
-5.0%
23.0%
Q2 25
26.1%
11.8%
Q1 25
0.1%
6.8%
Q4 24
-20.9%
19.3%
Q3 24
25.3%
27.3%
Q2 24
30.7%
24.3%
Q1 24
-7.1%
24.0%
Capex Intensity
IMCR
IMCR
RGEN
RGEN
Q4 25
2.8%
4.1%
Q3 25
0.7%
2.5%
Q2 25
0.4%
3.9%
Q1 25
0.3%
2.1%
Q4 24
4.3%
3.2%
Q3 24
1.0%
4.5%
Q2 24
0.4%
3.1%
Q1 24
0.6%
5.5%
Cash Conversion
IMCR
IMCR
RGEN
RGEN
Q4 25
1.93×
Q3 25
3.23×
Q2 25
1.92×
Q1 25
0.09×
2.57×
Q4 24
Q3 24
2.42×
Q2 24
12.70×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons